$NDRA PR ENDRA Life Sciences Granted U.S. Patent for Determining Fractional Fat Content of Tissue
Credit Suisse Starts MacroGenics $MGNX at Outperform PT $29
$CASI: CASI Pharma signs a license agreement for exclusive worldwide rights to the investigational anti-CD38 monoclonal antibody (Mab) TSK011010 program from Black Belt Therapeutics Limited (3.28)
Marker Therapeutics, Inc. ("Marker" or the "Company") previously communicated its understanding that Baylor College of Medicine ("BCM") clinicians would present initial clinical data with our MultiTAA T cell therapy in pancreatic cancer in the second quarter at the upcoming American Society of Clinical Oncology ("ASCO") meeting. BCM submitted its abstract to ASCO’s Trials in Progress ("TIP") track. As ASCO’s rules prohibit the inclusion of clinical outcome data in TIP abstract submissions, BCM’s clinical trial design abstract did not include any clinical data. The abstract was not accepted by ASCO.
Marker now expects to report more mature data from the BCM’s ongoing pancreatic study in the third quarter.